Intransal use buserelin, a GnRH agonist

S. Bianchi, L. Fedele, P. Vercellini, G. C. Carmosino, G. B. Candiani

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

GnRH agonists are now used in gynecologic practice in all clinical conditions requiring inhibition of pituitary-gonadal axis. Treatment with I.N. buserelin has been demonstrated effective in the management of these various conditions, despite the different degree of pituitary-ovarian suppression theoretically required to obtain the optimal therapeutic effect, since by modulating the dosage and frequency of administration of the drug it is possible to achieve different degree of suppression. In conditions like breast cancer, in which a rapid and sustained inhibition of ovarian activity is expected, I.N. formulation would not seem the most suitable. On the contrary, the I.N. formulation is the only feasible one for contraception since in this case adequate estrogen levels should be maintained to avoid the effects of hypoestrogenism on bone and to allow an artificial cycle with the addition of a progestogen. In the treatment of endometriosis and uterine leimyomas I.N. buserelin has been found as effective as subcutaneous treatment and with less severe side effects. Furthermore, there is no clinical difference between the two administration modalities in reproductive success after stimulation of ovulation with gonadotropins for which theoretically complete pituitary-gonadal suppression is required. Unless it is shown that the above clinical conditions require a complete medical castration, I.N. buserelin will probably become the medical therapeutic modality of choice in the near future. A real step forward in the treatment with GnRH agonists will be made when their pharmacologic characteristics and mechanism of action are better understood.

Original languageEnglish
Title of host publicationAdvances in Contraceptive Delivery Systems
Pages287-314
Number of pages28
Volume5
Edition3-4
Publication statusPublished - 1989

Fingerprint

Buserelin
Gonadotropin-Releasing Hormone
Therapeutics
Castration
Therapeutic Uses
Progestins
Endometriosis
Ovulation
Gonadotropins
Contraception
Estrogens
Breast Neoplasms
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Bianchi, S., Fedele, L., Vercellini, P., Carmosino, G. C., & Candiani, G. B. (1989). Intransal use buserelin, a GnRH agonist. In Advances in Contraceptive Delivery Systems (3-4 ed., Vol. 5, pp. 287-314)

Intransal use buserelin, a GnRH agonist. / Bianchi, S.; Fedele, L.; Vercellini, P.; Carmosino, G. C.; Candiani, G. B.

Advances in Contraceptive Delivery Systems. Vol. 5 3-4. ed. 1989. p. 287-314.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bianchi, S, Fedele, L, Vercellini, P, Carmosino, GC & Candiani, GB 1989, Intransal use buserelin, a GnRH agonist. in Advances in Contraceptive Delivery Systems. 3-4 edn, vol. 5, pp. 287-314.
Bianchi S, Fedele L, Vercellini P, Carmosino GC, Candiani GB. Intransal use buserelin, a GnRH agonist. In Advances in Contraceptive Delivery Systems. 3-4 ed. Vol. 5. 1989. p. 287-314
Bianchi, S. ; Fedele, L. ; Vercellini, P. ; Carmosino, G. C. ; Candiani, G. B. / Intransal use buserelin, a GnRH agonist. Advances in Contraceptive Delivery Systems. Vol. 5 3-4. ed. 1989. pp. 287-314
@inbook{ab91a55875634a5fbce1d6ff072c8fda,
title = "Intransal use buserelin, a GnRH agonist",
abstract = "GnRH agonists are now used in gynecologic practice in all clinical conditions requiring inhibition of pituitary-gonadal axis. Treatment with I.N. buserelin has been demonstrated effective in the management of these various conditions, despite the different degree of pituitary-ovarian suppression theoretically required to obtain the optimal therapeutic effect, since by modulating the dosage and frequency of administration of the drug it is possible to achieve different degree of suppression. In conditions like breast cancer, in which a rapid and sustained inhibition of ovarian activity is expected, I.N. formulation would not seem the most suitable. On the contrary, the I.N. formulation is the only feasible one for contraception since in this case adequate estrogen levels should be maintained to avoid the effects of hypoestrogenism on bone and to allow an artificial cycle with the addition of a progestogen. In the treatment of endometriosis and uterine leimyomas I.N. buserelin has been found as effective as subcutaneous treatment and with less severe side effects. Furthermore, there is no clinical difference between the two administration modalities in reproductive success after stimulation of ovulation with gonadotropins for which theoretically complete pituitary-gonadal suppression is required. Unless it is shown that the above clinical conditions require a complete medical castration, I.N. buserelin will probably become the medical therapeutic modality of choice in the near future. A real step forward in the treatment with GnRH agonists will be made when their pharmacologic characteristics and mechanism of action are better understood.",
author = "S. Bianchi and L. Fedele and P. Vercellini and Carmosino, {G. C.} and Candiani, {G. B.}",
year = "1989",
language = "English",
volume = "5",
pages = "287--314",
booktitle = "Advances in Contraceptive Delivery Systems",
edition = "3-4",

}

TY - CHAP

T1 - Intransal use buserelin, a GnRH agonist

AU - Bianchi, S.

AU - Fedele, L.

AU - Vercellini, P.

AU - Carmosino, G. C.

AU - Candiani, G. B.

PY - 1989

Y1 - 1989

N2 - GnRH agonists are now used in gynecologic practice in all clinical conditions requiring inhibition of pituitary-gonadal axis. Treatment with I.N. buserelin has been demonstrated effective in the management of these various conditions, despite the different degree of pituitary-ovarian suppression theoretically required to obtain the optimal therapeutic effect, since by modulating the dosage and frequency of administration of the drug it is possible to achieve different degree of suppression. In conditions like breast cancer, in which a rapid and sustained inhibition of ovarian activity is expected, I.N. formulation would not seem the most suitable. On the contrary, the I.N. formulation is the only feasible one for contraception since in this case adequate estrogen levels should be maintained to avoid the effects of hypoestrogenism on bone and to allow an artificial cycle with the addition of a progestogen. In the treatment of endometriosis and uterine leimyomas I.N. buserelin has been found as effective as subcutaneous treatment and with less severe side effects. Furthermore, there is no clinical difference between the two administration modalities in reproductive success after stimulation of ovulation with gonadotropins for which theoretically complete pituitary-gonadal suppression is required. Unless it is shown that the above clinical conditions require a complete medical castration, I.N. buserelin will probably become the medical therapeutic modality of choice in the near future. A real step forward in the treatment with GnRH agonists will be made when their pharmacologic characteristics and mechanism of action are better understood.

AB - GnRH agonists are now used in gynecologic practice in all clinical conditions requiring inhibition of pituitary-gonadal axis. Treatment with I.N. buserelin has been demonstrated effective in the management of these various conditions, despite the different degree of pituitary-ovarian suppression theoretically required to obtain the optimal therapeutic effect, since by modulating the dosage and frequency of administration of the drug it is possible to achieve different degree of suppression. In conditions like breast cancer, in which a rapid and sustained inhibition of ovarian activity is expected, I.N. formulation would not seem the most suitable. On the contrary, the I.N. formulation is the only feasible one for contraception since in this case adequate estrogen levels should be maintained to avoid the effects of hypoestrogenism on bone and to allow an artificial cycle with the addition of a progestogen. In the treatment of endometriosis and uterine leimyomas I.N. buserelin has been found as effective as subcutaneous treatment and with less severe side effects. Furthermore, there is no clinical difference between the two administration modalities in reproductive success after stimulation of ovulation with gonadotropins for which theoretically complete pituitary-gonadal suppression is required. Unless it is shown that the above clinical conditions require a complete medical castration, I.N. buserelin will probably become the medical therapeutic modality of choice in the near future. A real step forward in the treatment with GnRH agonists will be made when their pharmacologic characteristics and mechanism of action are better understood.

UR - http://www.scopus.com/inward/record.url?scp=0024441961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024441961&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0024441961

VL - 5

SP - 287

EP - 314

BT - Advances in Contraceptive Delivery Systems

ER -